Abbott Laboratories
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert Ford
- Full Time Employees
- 114,000
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 100 Abbott Park Road Abbott Park IL United States of America 60064-6400
- IPO Date
- Mar 17, 1980
- CIK
- 0000001800
- Website
- abbott.com
- Similar Companies
- Business
- Abbott Laboratories (NYSE: ABT) develops, manufactures, and sells a broad range of health care products worldwide. The company operates through four main segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices; its core offerings include branded generic pharmaceuticals such as Branded generics in emerging markets, anti-infectives, and gastrointestinal drugs; diagnostics encompassing point-of-care testing systems like i-STAT, molecular diagnostics via Alinity platforms, rapid diagnostics under BinaxNOW and Determine brands, and core laboratory instruments; nutritional products including pediatric formulas like Similac and Pediasure, adult nutritionals such as Ensure and Glucerna, and medical foods; as well as medical devices featuring cardiovascular and neuromodulation devices including FreeStyle Libre continuous glucose monitoring systems, Aveir leadless pacemakers, TactiFlex ablation catheters, and structural heart devices like Amplatzer occluders. Abbott serves health care professionals, consumers, hospitals, laboratories, and governments across more than 100 countries, with principal manufacturing facilities in the United States, Europe, Asia, and Latin America. Founded in 1888 and headquartered in Abbott Park, Illinois, the company maintains a diversified portfolio without notable subsidiaries or parent relationships impacting its core structure. In recent developments within the last two years, Abbott completed the acquisition of Cardiovascular Systems, Inc. in 2024 to expand its cardiovascular portfolio; launched the FreeStyle Libre 3 integrated continuous glucose monitoring sensor in multiple markets including the U.S.; introduced the AVEIR DR dual chamber leadless pacemaker system and the TactiFlex Sensor Enabled Ablation Catheter; formed strategic partnerships for digital health integrations and expanded diagnostics manufacturing capacity amid global demand surges; and reported strong growth in its diabetes and cardiovascular segments during 2025 earnings.
Abbott Laboratories Q2 Earnings Preview: A Contrarian Buy Opportunity Worth Considering
5 Underperforming Dividend Kings Offer Big Passive Income and Huge Total Return Potential
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?
Here Are Wednesday's Best Wall Street Analyst Research Calls: Abbott Laboratories, Circle Internet, Dow, Kratos Defense, Lockheed Martin, Salesforce, ServiceNow,SpaceX, and More
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know
Value stocks beat growth when inflation is high. Here are 13 stocks top newsletters are betting on now.
3 No-Brainer Dividend Stocks to Buy Right Now
How Abbott's Largest Segment Is Preparing for the Next Growth Phase
US DOJ closes criminal probe into Abbott over baby formula plant, WSJ reports
The Baby Formula Probe Produced a Pile of Evidence. Then the DOJ Dropped the Case.
In a Volatile Market, This Dividend Growth Stock Is Worth Every Penny of $1,000
Abbott vs. DexCom: Which CGM Stock Is the Better Option Right Now?
Buy, Hold, or Sell: Tech Compression Dragged Abbott Labs Under $91, but 1 Massive Diabetes Catalyst Makes It a Screaming Buy
Abbott hosts conference call for second-quarter earnings
Got $2,500? 1 Unstoppable Dividend Aristocrat With an Ironclad Moat to Buy
MiniMed Launches Abbott's Instinct Sensors Across European Markets
How Are Emerging Markets Supporting Abbott's EPD Momentum?
ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease Testing
ALZpath signs licensing deal with Abbott to develop Alzheimer's blood test